Literature DB >> 6776155

Clinical applications of immunofixation: detection and quantitation of complement activation.

J T Whicher, J Higginson, P G Riches, S Radford.   

Abstract

The methods currently in use for the detection and quantitation of complement activation products are slow and time consuming. We describe a method utilising immunofixation after agarose or cellulose acetate membrane electrophoresis which allows large batches of samples to be screened rapidly for the presence of activation products of C3 and factor B. Further, after immunofixation on agarose the conversion product may be quantitated by densitometry. This method gives similar results to those obtained by crossed immunoelectrophoresis. Using both this technique and crossed immunoelectrophoresis we have been able to confirm that C4 activation occurs during electrophoresis in the absence of EDTA and that in the presence of EDTA it is not demonstrable even in patients with active immune complex disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776155      PMCID: PMC1146217          DOI: 10.1136/jcp.33.8.781

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  In vivo activation of C3 revealed by crossed immunoelectrophoresis as a parameter of immunological activity in disease.

Authors:  P Teisberg
Journal:  Clin Chim Acta       Date:  1975-07-09       Impact factor: 3.786

2.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

3.  Conversion of the fourth complement component studied by crossed immunoelectrophoresis.

Authors:  A G Sjöholm; A B Laurell
Journal:  Clin Exp Immunol       Date:  1973-08       Impact factor: 4.330

4.  Immunofixation electrophoresis: a technique for the study of protein polymorphism.

Authors:  C A Alper; A M Johnson
Journal:  Vox Sang       Date:  1969-11       Impact factor: 2.144

5.  Boomslang bite with haemorrhage and activation of complement by the alternate pathway.

Authors:  I C Nicolson; P A Ashby; N D Johnson; J Versey; L Slater
Journal:  Clin Exp Immunol       Date:  1974-02       Impact factor: 4.330

6.  Complement activation in pemphigus vulgaris blister fluid.

Authors:  R E Jordan; N K Day; J R Luckasen; R A Good
Journal:  Clin Exp Immunol       Date:  1973-09       Impact factor: 4.330

7.  Structural polymorphism of the fourth component of human complement.

Authors:  S I Rosenfeld; S Ruddy; K F Austen
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

8.  Changes in antigenic properties of human C3 upon activation and conversion by trypsin.

Authors:  J L Molenaar; M A Müller; C P Engelfriet; K W Pondman
Journal:  J Immunol       Date:  1974-04       Impact factor: 5.422

9.  A multi-sample applicator for zone electrophoresis.

Authors:  J Kohn
Journal:  Clin Chim Acta       Date:  1967-10       Impact factor: 3.786

10.  Genetic polymorphism in human glycine-rich beta-glycoprotein.

Authors:  C A Alper; T Boenisch; L Watson
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

View more
  12 in total

1.  Effect of lithium therapy on inflammatory response.

Authors:  J W O'Riordan; D Kelleher; Y Williams; F J Bloomfield
Journal:  Inflammation       Date:  1986-03       Impact factor: 4.092

2.  C3 and C4 complement components and acute phase proteins in late pregnancy and parturition.

Authors:  I Z Kovar; P G Riches
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

3.  Acetaldehyde alone may initiate hepatocellular damage in acute alcoholic liver disease.

Authors:  R E Barry; J D McGivan
Journal:  Gut       Date:  1985-10       Impact factor: 23.059

4.  Influence of lithium and fluoride on degranulation from human neutrophils in vitro.

Authors:  F J Bloomfield; M M Young
Journal:  Inflammation       Date:  1982-09       Impact factor: 4.092

5.  Complement activation and complement control proteins in acute pancreatitis.

Authors:  J T Whicher; M P Barnes; A Brown; M J Cooper; R Read; G Walters; R C Williamson
Journal:  Gut       Date:  1982-11       Impact factor: 23.059

6.  Clinical application of a new nephelometric technique to measure complement activation.

Authors:  D Vergani; L Bevis; B A Nasaruddin; G Mieli-Vergani; D E Tee
Journal:  J Clin Pathol       Date:  1983-07       Impact factor: 3.411

7.  Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.

Authors:  R G Bredius; P C Driedijk; M F Schouten; R S Weening; T A Out
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

8.  CR1 deficiency in SLE: acquired or genetic?

Authors:  G Uko; R L Dawkins; P Kay; F T Christiansen; P N Hollingsworth
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

9.  Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles.

Authors:  M Doherty; J T Whicher; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1983-06       Impact factor: 19.103

10.  Complement activation by circulating serum factors in human glomerulonephritis.

Authors:  S Meri
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.